Senores Pharmaceuticals has notified stock exchanges of an upcoming Board of Directors meeting scheduled for Thursday, May 14, 2026, in compliance with Regulation 29 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 08, 2026, and signed by Vinay Kumar Mishra, Company Secretary and Compliance Officer.

Board Meeting Agenda

The Board meeting has been convened to transact the following key business:

• Consider and approve the Audited Consolidated and Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026
• Transact other business matters as may arise during the meeting

The key details of the scheduled board meeting are summarised below:

Trading Window Closure

In connection with the upcoming board meeting, Senores Pharmaceuticals had previously issued an intimation dated March 27, 2026, notifying the closure of the Trading Window for dealing in the company's securities. The closure applies to persons specified under the Company's Code of Conduct, framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The Trading Window was closed effective April 01, 2026, and will remain shut until 48 hours after the Audited Consolidated and Standalone Financial Results for the quarter and financial year ended March 31, 2026 are approved by the Board of Directors and submitted to the stock exchanges.

Signatory Details

The regulatory filing was submitted by Vinay Kumar Mishra, Company Secretary and Compliance Officer of Senores Pharmaceuticals, bearing ICSI Membership No. F11464. The document was digitally signed on May 08, 2026, at 17:03:45 +05'30".

Senores Pharmaceuticals is headquartered at 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India.

Senores Pharmaceuticals Limited has filed its annual encumbrance disclosure with stock exchanges, fulfilling regulatory requirements under the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure pertains to the financial year ended March 31, 2026, and was submitted on April 02, 2026.

Regulatory Compliance Filing

The annual disclosure was submitted pursuant to Regulation 31(4) of the SAST Regulations, which mandates promoters and promoter groups to disclose any encumbrances made on their shareholdings. Company Secretary and Compliance Officer Vinay Kumar Mishra submitted the filing to both BSE Limited and National Stock Exchange of India Limited on behalf of the company.

Promoter Declaration

Swapnil Jatinbhai Shah, promoter of Senores Pharmaceuticals Limited, submitted the disclosure on behalf of all promoters, promoter group members, and persons acting in concert. The declaration confirms that no new encumbrances were created on shares held by the promoter group during the financial year ended March 31, 2026.

Stock Exchange Submission

The disclosure was formally submitted to both major Indian stock exchanges where the company's shares are listed. The filing ensures transparency regarding promoter shareholding patterns and any potential encumbrances that could affect shareholder interests.

The company emphasized that while no new encumbrances were created during the financial year, any previously disclosed encumbrances to the stock exchanges remain on record. This annual filing represents part of the company's ongoing compliance with securities market regulations designed to protect investor interests and maintain market transparency.